Oral Lyophylizate Formulation of Desmopressin: Superior Pharmacodynamics Compared to Tablet Due to Low Food Interaction
- 1 June 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (6) , 2308-2313
Abstract
Desmopressin is a standard treatment for monosymptomatic nocturnal enuresis. Different formulations are promoted as bioequivalent, although these claims are not supported by comparative pharmacodynamic data in children. Food interaction is known to influence the bioavailability of desmopressin. We compared the pharmacodynamics of the 2 most frequently used desmopressin formulations, tablet and lyophilizate, with a standardized meal, allowing extrapolation to clinical reality, where the interval between evening meal and medication intake is limited for school-age children. We hypothesized there would be a faster pharmacodynamic response, and greater concentrating and antidiuretic activity for the fast dissolving (melt) formulation compared to the tablet with simultaneous food intake. Two tests were performed on separate days in identical standardized conditions, starting with a 15 ml/kg water load. After achieving maximal diluting capacity a standardized meal was administered, followed by desmopressin tablet (t test) or melt (M-test). Diuresis rate and urinary osmolality were measured hourly. Paired data from 4 girls and 15 boys with a mean age of 12.1 years were obtained. In the early response phase more than 25% of patients had a higher diuresis rate with tablet vs melt formulation, reaching statistical significance in the plateau phase (urine collected at hours 3 to 5, p <0.02) and in duration of action (urine collected at hours 5 to 8, p <0.005). For desmopressin melt smaller standard deviations in diuresis rate were remarkable. Concentrating capacity demonstrated no significant differences between formulations in the early response phase, in contrast to the plateau phase (p <0.036) and duration of action (p <0.001). With meal combination desmopressin melt formulation has a superior pharmacodynamic profile to tablet, making it more suitable for the younger age group with a limited interval between meal and drug administration.Keywords
This publication has 21 references indexed in Scilit:
- Poor Compliance With Primary Nocturnal Enuresis Therapy May Contribute to Insufficient Desmopressin ResponseJournal of Urology, 2009
- Abnormal Sleep Architecture and Refractory Nocturnal EnuresisJournal of Urology, 2009
- Evidence of Partial Anti-Enuretic Response Related to Poor Pharmacodynamic Effects of Desmopressin Nasal SprayJournal of Urology, 2009
- Partial Response to Intranasal Desmopressin in Children With Monosymptomatic Nocturnal Enuresis is Related to Persistent Nocturnal Polyuria on Wet NightsJournal of Urology, 2007
- A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresisInternational Journal Of Clinical Practice, 2007
- Nocturnal polyuria in monosymptomatic nocturnal enuresis refractory to desmopressin treatmentAmerican Journal of Physiology-Renal Physiology, 2006
- Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy AdultsThe Journal of Clinical Pharmacology, 2006
- A new fast‐melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresisBJU International, 2006
- The pharmacokinetics of 400 µg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effectBJU International, 2005
- A Clinical and Pharmacological Model for Explaining Response to DesmopressinScandinavian Journal of Urology and Nephrology, 1999